

## Home Study CE:

### Are you feeling compelled?: ASCVD Risk Reduction and Type 2 Diabetes Mellitus

#### Summary of Program

Type 2 Diabetes Mellitus (T2DM) affects more than 34 million people and is the 7<sup>th</sup> leading cause of death in the United States according to the Centers for Disease Control and Prevention. Atherosclerotic cardiovascular disease (ASCVD) events such as heart attacks and strokes are twice as likely to occur in people with diabetes. Several recent trials have led to the FDA adding indications for ASCVD risk reduction to medications used for the treatment of T2DM. This program will discuss those studies and subsequent guideline and FDA indication changes.

Assessment Questions (Select all that apply)

1. Which GLP1 RAs have an FDA indication for reduction of ASCVD events in people with diabetes and established cardiovascular disease?
  - a. Rybelsus (semaglutide oral)
  - b. Trulicity (dulaglutide)
  - c. Victoza (liraglutide)
  - d. Byetta (exenatide)
  - e. Adlyxin (lixesenatide)
  - f. Ozempic (semaglutide injection)
  - g. Bydureon (exenatide LAR)
2. Which SGLT2i medications have an FDA indication for reduction of ASCVD events in people with diabetes and established cardiovascular disease?
  - a. Invokana (canagliflozin)
  - b. Jardiance (empagliflozin)
  - c. Farxiga (dapagliflozin)
  - d. Steglatro (empagliflozin)
3. Which medication had an FDA indication for treatment of heart failure in patients without diabetes?
  - a. Glucophage (metformin)
  - b. Actos (pioglitazone)
  - c. Trulicity (dulaglutide)
  - d. Farxiga (dapagliflozin)
4. Which medication has an FDA indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors?
  - a. Jardiance (empagliflozin)
  - b. Ozempic (semaglutide)
  - c. Trulicity (dulaglutide)
  - d. Tradjenta (linagliptin)